Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
493
mi
from 43215
Birmingham, AL
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
493
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
University of Louisville
188
mi
from 43215
Louisville, KY
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
University of Louisville
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Tulane University
797
mi
from 43215
New Orleans, LA
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Tulane University
797
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Maine Medical Center
704
mi
from 43215
Portland, ME
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Maine Medical Center
704
mi
from 43215
Portland, ME
Click here to add this to my saved trials
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
University of Massachusetts Medical Center
607
mi
from 43215
Worcester, MA
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
University of Massachusetts Medical Center
607
mi
from 43215
Worcester, MA
Click here to add this to my saved trials
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
New York Presbyterian Hospital-Weill Cornell Medical Center
480
mi
from 43215
New York, NY
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
New York Presbyterian Hospital-Weill Cornell Medical Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Keck University Hospital at USC
1972
mi
from 43215
Los Angeles, CA
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Keck University Hospital at USC
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
RenalCare Associates, S.C.
348
mi
from 43215
Peoria, IL
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
RenalCare Associates, S.C.
348
mi
from 43215
Peoria, IL
Click here to add this to my saved trials
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
344
mi
from 43215
Chapel Hill, NC
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
344
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
SC Nephrology & Hypertension Ctr
463
mi
from 43215
Orangeburg, SC
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
SC Nephrology & Hypertension Ctr
463
mi
from 43215
Orangeburg, SC
Click here to add this to my saved trials
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
University of Alberta
1700
mi
from 43215
Edmonton,
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
University of Alberta
1700
mi
from 43215
Edmonton,
Click here to add this to my saved trials
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Banner University Medical Center - Tucson
1639
mi
from 43215
Tucson, AZ
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Banner University Medical Center - Tucson
1639
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
Ides in Highly Sensitized Patients Awaiting Kidney Transplantation
A Phase I/II Trial to Evaluate the Safety and Tolerability of Ides® (IgG Endopeptidase) to Eliminate Donor Specific HLA Antibodies (DSAs) and Prevent Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients.
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
1972
mi
from 43215
Los Angeles, CA
Ides in Highly Sensitized Patients Awaiting Kidney Transplantation
A Phase I/II Trial to Evaluate the Safety and Tolerability of Ides® (IgG Endopeptidase) to Eliminate Donor Specific HLA Antibodies (DSAs) and Prevent Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients.
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients
A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
University of Illinois Hospital & Health Sciences System
274
mi
from 43215
Chicago, IL
A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients
A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
University of Illinois Hospital & Health Sciences System
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Status: Enrolling
Updated:  12/31/1969
Eastern Nephrology Associates
429
mi
from 43215
Greenville, NC
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Status: Enrolling
Updated: 12/31/1969
Eastern Nephrology Associates
429
mi
from 43215
Greenville, NC
Click here to add this to my saved trials
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Status: Enrolling
Updated:  12/31/1969
Eastern Nephology Associates
480
mi
from 43215
New Bern, NC
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Status: Enrolling
Updated: 12/31/1969
Eastern Nephology Associates
480
mi
from 43215
New Bern, NC
Click here to add this to my saved trials
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Status: Enrolling
Updated:  12/31/1969
Capital Nephrology Associates
374
mi
from 43215
Raleigh, NC
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Status: Enrolling
Updated: 12/31/1969
Capital Nephrology Associates
374
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Status: Enrolling
Updated:  12/31/1969
South Carolina Nephrology & Hypertension Center
463
mi
from 43215
Orangeburg, SC
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Status: Enrolling
Updated: 12/31/1969
South Carolina Nephrology & Hypertension Center
463
mi
from 43215
Orangeburg, SC
Click here to add this to my saved trials
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Status: Enrolling
Updated:  12/31/1969
Lubbock Vascular Access Centre
1133
mi
from 43215
Lubbock, TX
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Status: Enrolling
Updated: 12/31/1969
Lubbock Vascular Access Centre
1133
mi
from 43215
Lubbock, TX
Click here to add this to my saved trials
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Status: Enrolling
Updated:  12/31/1969
Renal Associates, PA
1138
mi
from 43215
San Antonio, TX
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Status: Enrolling
Updated: 12/31/1969
Renal Associates, PA
1138
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Group-based Chronic Kidney Disease Care
Group-based Chronic Kidney Disease Care
Status: Enrolling
Updated:  12/31/1969
Albert Einstein College of Medicine
486
mi
from 43215
Bronx, NY
Group-based Chronic Kidney Disease Care
Group-based Chronic Kidney Disease Care
Status: Enrolling
Updated: 12/31/1969
Albert Einstein College of Medicine
486
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
A Two-Arm, Open-Label, Standard of Care Control Evaluation of Ferric Citrate for the Transition From Chronic Kidney Disease Stage 4/5 to Chronic Kidney Stage 5D
Status: Enrolling
Updated:  12/31/1969
Denver Nephrologists, PC
1157
mi
from 43215
Denver, CO
Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
A Two-Arm, Open-Label, Standard of Care Control Evaluation of Ferric Citrate for the Transition From Chronic Kidney Disease Stage 4/5 to Chronic Kidney Stage 5D
Status: Enrolling
Updated: 12/31/1969
Denver Nephrologists, PC
1157
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
97
mi
from 43215
Cincinnati, OH
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
97
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Stanford University
2100
mi
from 43215
Palo Alto, CA
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Stanford University
2100
mi
from 43215
Palo Alto, CA
Click here to add this to my saved trials
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Nemours Orlando A.I. DuPont Hospital for Children
mi
from 43215
Jacksonville, FL
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Nemours Orlando A.I. DuPont Hospital for Children
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
University of Miami
992
mi
from 43215
Miami, FL
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
University of Miami
992
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
University of Iowa
461
mi
from 43215
Iowa City, IA
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
University of Iowa
461
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Medicine
345
mi
from 43215
Baltimore, MD
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Medicine
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
East Carolina University
429
mi
from 43215
Greenville, NC
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
East Carolina University
429
mi
from 43215
Greenville, NC
Click here to add this to my saved trials
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
337
mi
from 43215
Hershey, PA
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
337
mi
from 43215
Hershey, PA
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1922
mi
from 43215
Colton, CA
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1922
mi
from 43215
Colton, CA
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1960
mi
from 43215
Santa Ana, CA
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1960
mi
from 43215
Santa Ana, CA
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1161
mi
from 43215
Colorado Springs, CO
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1161
mi
from 43215
Colorado Springs, CO
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
789
mi
from 43215
Brooksville, FL
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
789
mi
from 43215
Brooksville, FL
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
772
mi
from 43215
Debary, FL
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
772
mi
from 43215
Debary, FL
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
989
mi
from 43215
Hialeah, FL
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
989
mi
from 43215
Hialeah, FL
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
810
mi
from 43215
Kissimmee, FL
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
810
mi
from 43215
Kissimmee, FL
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
993
mi
from 43215
Miami, FL
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
208
mi
from 43215
Grand Blanc, MI
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
208
mi
from 43215
Grand Blanc, MI
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
322
mi
from 43215
High Point, NC
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
322
mi
from 43215
High Point, NC
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
373
mi
from 43215
Wyomissing, PA
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
373
mi
from 43215
Wyomissing, PA
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
351
mi
from 43215
Greer, SC
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
351
mi
from 43215
Greer, SC
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1071
mi
from 43215
Rapid City, SD
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1071
mi
from 43215
Rapid City, SD
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
283
mi
from 43215
Knoxville, TN
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
283
mi
from 43215
Knoxville, TN
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
991
mi
from 43215
Houston, TX
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
896
mi
from 43215
Plano, TX
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
896
mi
from 43215
Plano, TX
Click here to add this to my saved trials
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
138
mi
from 43215
Charleston, WV
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
138
mi
from 43215
Charleston, WV
Click here to add this to my saved trials